Literature DB >> 19573741

Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health.

Murali Sundaram1, Michael J Smith, Dennis A Revicki, Betsy Elswick, Lesley-Ann Miller.   

Abstract

OBJECTIVE: To develop a classification system (CS) for a diabetes-specific preference-based measure of health titled the Diabetes Utility Index (DUI). STUDY DESIGN AND
SETTING: Factor analysis of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) items (n=385) identified plausible attributes. An expert panel provided qualitative input, including additional items. Data from three pilot rounds on patients with type 1 or type 2 diabetes were analyzed using Rasch analysis (RA). In a validation survey, the final version of the CS was mailed along with the SF-12v2, Well-Being Questionnaire, and Diabetes Empowerment Scale Short Form to a convenience sample (type 1 or type 2 diabetes).
RESULTS: Factor analysis identified two plausible attributes. Experts rated the importance of ADDQoL and additional items, described attributes from item sets and suggested severity levels. Three pilot rounds (n1=52, n2=65, n3=111) tested versions of a CS, containing five attributes with severity levels that were modified using RA and expert input. The final attributes were Physical Ability and Energy, Relationships, Mood and Feelings, Enjoyment of Diet, and Satisfaction with Management of Diabetes. The validation survey (n=396) results indicated satisfactory Rasch fit statistics, reliability, and severity scaling, whereas correspondence of responses to the CS with included measures suggested validity.
CONCLUSION: Results provide initial report of the validity and reliability of the CS of the DUI.

Entities:  

Mesh:

Year:  2009        PMID: 19573741     DOI: 10.1016/j.jclinepi.2009.01.020

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  Valuation of depression co-occurring with a somatic condition: feasibility of the time trade-off task.

Authors:  Katerina Papageorgiou; Karin M Vermeulen; Fenna R M Leijten; Erik Buskens; Adelita V Ranchor; Maya J Schroevers
Journal:  Health Expect       Date:  2014-11-13       Impact factor: 3.377

Review 2.  A review and critique of studies reporting utility values for schizophrenia-related health states.

Authors:  Ifigeneia Mavranezouli
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  Estimation of a valuation function for a diabetes mellitus-specific preference-based measure of health: the Diabetes Utility Index.

Authors:  Murali Sundaram; Michael J Smith; Dennis A Revicki; Lesley-Ann Miller; Suresh Madhavan; Gerry Hobbs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study.

Authors:  W E Schmidt; J S Christiansen; M Hammer; M J Zychma; J B Buse
Journal:  Diabet Med       Date:  2011-06       Impact factor: 4.359

6.  Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions.

Authors:  Teresa C O Tsui; Maureen Trudeau; Nicholas Mitsakakis; Sofia Torres; Karen E Bremner; Doyoung Kim; Aileen M Davis; Murray D Krahn
Journal:  PLoS One       Date:  2022-02-04       Impact factor: 3.240

7.  Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D.

Authors:  Ifigeneia Mavranezouli; John E Brazier; Donna Rowen; Michael Barkham
Journal:  Med Decis Making       Date:  2012-11-25       Impact factor: 2.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.